Literature DB >> 8913486

Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.

E Fasola1, S K Spangler, L M Ednie, M R Jacobs, S Bajaksouzian, P C Appelbaum.   

Abstract

Microdilution MIC testing was used to test the susceptibility of 202 pneumococci to LY 333328 and six other agents. LY 333328 was the most active glycopeptide (MIC at which 90% of the pneumococci were inhibited [MIC90], 0.008 microgram/ml), followed by teicoplanin (MIC90, 0.06 microgram/ml) and vancomycin (MIC90, 0.5 microgram/ml). Rifampin resistance was seen in some penicillin-resistant strains. The MICs of imipenem and ceftriaxone rose with those of penicillin. Time-kill testing confirmed the excellent antipneumococcal activity of LY 333328.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8913486      PMCID： PMC163597     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 2.  Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.

Authors:  M M París; O Ramilo; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

3.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 4.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

5.  Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group.

Authors:  F W Goldstein; P Geslin; J F Acar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

6.  Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 8.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

9.  Evaluation of vancomycin for therapy of adult pneumococcal meningitis.

Authors:  P F Viladrich; F Gudiol; J Liñares; R Pallarés; I Sabaté; G Rufí; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

10.  Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.

Authors:  K P Klugman; R Dagan
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
View more
  7 in total

1.  Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.

Authors:  J Gerber; A Smirnov; A Wellmer; J Ragheb; J Prange; E Schütz; K Wettich; S Kalich; R Nau
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

4.  In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.

Authors:  F García-Garrote; E Cercenado; L Alcalá; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.

Authors:  M L Zeckel; D A Preston; B S Allen
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.

Authors:  Carmen Cabellos; Antonio Fernàndez; Jose M Maiques; Fe Tubau; Carmen Ardanuy; Pedro F Viladrich; Josefina Liñares; Francesc Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 7.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.